CPC Biotech Collaborates with Multiply Labs to Advance Cell Therapy Automation

Rhea-AI Summary

CPC Biotech, part of PSG and Dover (NYSE:DOV), announced a collaboration with Multiply Labs to advance robotic automation in cell therapy manufacturing. CPC Biotech is developing a robot-optimized aseptic connector using its MicroCNX® Nano Series to support scalable, efficient, contamination‑reducing production.

AI-generated analysis. Not financial advice.

Market Reality Check

Price: $215.40 Vol: Volume 923,205 is 1.11x t...

normal vol

$215.40 Last Close

Volume Volume 923,205 is 1.11x the 20-day average of 835,208, indicating modestly elevated activity pre-announcement. normal

Technical Shares at $215.40 were trading above the 200-day MA of $197.19 and about 9.32% below the 52-week high.

Peers on Argus

Peers showed mixed moves: IR +1.22%, GGG +0.77%, XYL roughly flat, while PNR -2....

Peers showed mixed moves: IR +1.22%, GGG +0.77%, XYL roughly flat, while PNR -2.30% and SYM -4.77%. With DOV up 2.62% and no peers in the momentum scanner, the move appears stock-specific rather than sector-driven.

Previous Partnership Reports

3 past events · Latest: Apr 21 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Apr 21	Strategic partnership	Positive	-1.1%	SWEP partnership to add printed circuit heat exchangers to portfolio.
Aug 27	Automation collaboration	Positive	-0.6%	Collaboration to automate about 1,000 fuel pumps across Nigeria.
Jul 15	Partnership expansion	Positive	+0.4%	Expanded global partnership to roll out BX supply chain platform.

Pattern Detected

Partnership and collaboration announcements have often seen flat-to-negative next-day reactions despite strategically positive framing.

Recent Company History

Over the past year, Dover and its businesses have announced several partnerships aimed at expanding technology and market reach. On Jul 15, 2025, Dover Fueling Solutions expanded a global partnership with Bottomline, with a modest +0.41% move afterward. A major collaboration with Ardova Plc on Aug 27, 2025 to automate 1,000 pumps in Nigeria saw a -0.61% reaction. More recently, on Apr 21, 2026, SWEP’s strategic partnership for printed circuit heat exchangers led to a -1.14% move. Against this backdrop, today’s cell-therapy automation collaboration fits the pattern of strategic but not always positively received news.

Historical Comparison

-0.5% avg move · In the past year, Dover’s partnership headlines averaged a -0.45% next-day move. Today’s +2.62% gain...

partnership

-0.5%

Average Historical Move partnership

In the past year, Dover’s partnership headlines averaged a -0.45% next-day move. Today’s +2.62% gain ahead of a new automation collaboration stands out versus that pattern.

Recent partnerships span fueling automation, supply-chain optimization, and advanced heat exchangers; this collaboration extends the theme into cell and gene therapy manufacturing automation.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-24

Dover has an effective automatic shelf registration on Form S-3ASR filed on Feb 24, 2026 for unsecured debt securities. Specific terms and sizes would be set in future prospectus supplements, with proceeds earmarked for general corporate purposes such as debt repayment, working capital, capital spending, investments, acquisitions, or share repurchases.

Market Pulse Summary

This announcement highlights Dover’s push into robotics-enabled cell and gene therapy manufacturing ...

Analysis

This announcement highlights Dover’s push into robotics-enabled cell and gene therapy manufacturing via CPC Biotech’s collaboration with Multiply Labs. It reinforces a broader strategy of partnerships following earlier agreements in fueling automation and heat transfer. Investors may watch for concrete indicators such as adoption rates of the new aseptic connector, any disclosed revenue contributions in future filings, and how management prioritizes capital deployment under its existing S-3ASR debt shelf.

Key Terms

cell therapy, gene therapy, cgT, sterile processing

4 terms

cell therapy medical

"Automation and the use of robotics are key to accelerating patient access to advanced therapies..."

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

gene therapy medical

"cell therapy and gene therapy (CGT) businesses."

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

cgT medical

"cell therapy and gene therapy (CGT) businesses."

CGT stands for capital gains tax, a tax on the profit an investor realizes when selling an asset such as stocks, property, or funds. It matters because it reduces the money you actually keep from a sale—like having to share part of a prize—so investors consider tax rates, how long they hold an asset, and timing of sales to maximize after-tax returns.

sterile processing medical

"self-contained sterile processing robotic system."

Sterile processing is the cleaning, disinfection and final sterilization of medical instruments and devices so they are free of germs before use, like washing and baking reusable kitchen tools to make them safe to use. For investors, it matters because effective sterile processing affects hospital and device-maker costs, regulatory compliance, patient safety and legal risk, all of which can influence revenues, reputation and cash flow.

AI-generated analysis. Not financial advice.

DOWNERS GROVE, Ill., May 27, 2026 /PRNewswire/ -- CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processing, has collaborated with Multiply Labs to rapidly advance the use of robotic systems in cell therapy manufacturing.

"Automation and the use of robotics are key to accelerating patient access to advanced therapies," said Troy Ostreng, Senior Product Manager for CPC Biotech's biopharmaceutical and cell therapy and gene therapy (CGT) businesses. "To meet the growing need for faster, more efficient, high-quality cell therapy manufacturing, we're developing a first-ever aseptic connector for robotic operation."

San Francisco-based Multiply Labs is a pioneer in applying robotics to the production of cell and gene therapy products. Their unique modular approach is designed to reduce manufacturing bottlenecks, minimize the risk of human contamination, and broaden access to therapies.

"Today, cell therapy is done completely manually," said Fred Parietti, Multiply Lab's Co-Founder and CEO. "With robotic automation, we can unlock a level of scale and affordability that has not been possible with manual approaches."

Human operators, a source of contamination risk, do not enter Multiply Lab's self-contained sterile processing robotic system. As a result, the system components must be effectively managed by robots. CPC Biotech's new robot-optimized solution combines the company's groundbreaking MicroCNX^® Nano Series aseptic connectors with a proprietary interface engineered for manipulation by robotic grippers.

"Robots still have difficulty handling soft material like bags or tubing," continued Ostreng. "A rigid connector at the end of tubing is something robotic grippers can operate in a stable, repeatable way. This new connector will help make robotics-based cell therapy automation possible."

Both CPC Biotech and Multiply Labs are committed to maximizing production capacity in a compact footprint. "It's important for us to fit easily on the production floor," added Parietti.

The companies are also focused on ease of use, modularity, and scalability. "Reliability, repeatability, and simplification will help cell therapy manufacturers adopt an automated approach with confidence," said Ostreng. "In the end, we're all working together to get therapies to the people who need them quickly, efficiently, and affordably."

For more information about the performance and versatility of MicroCNX connectors, please visit https://www.cpc-bio.com/applications-overview/industries/cell-therapy.

About CPC Biotech:

CPC Biotech is at the forefront of bioprocessing fluid management and flow control, offering a comprehensive portfolio of critical components: connectors, pumps, flow meters and sensors. Our industry-leading products permit biopharma innovators to produce next-generation biologics and therapeutics with optimal integrity, yield, efficiency and scalability. From lab to commercial launch, we enable those who drive breakthroughs in medicines and biologics that transform lives and advance humanity. CPC Biotech is part of Pump Solutions Group (PSG), an operating company within Dover Corporation. To learn more about CPC Biotech, please visit cpc-bio.com.

About PSG:

PSG is the global pump, metering and dispensing-solution expert, enabling the safe and efficient transfer of critical and valuable fluids that require optimal performance and reliability in applications where it matters most. Additionally, PSG is a leading provider of flow meters designed to reduce waste and downtime while accurately measuring, monitoring and controlling the distribution of fluids. Headquartered in Downers Grove, IL, USA, PSG is comprised of several world-class brands, including Abaque, All-Flo, Almatec, Blackmer, CPC Biotech, Cryo-Mach, Ebsray, em-tec, Griswold, Hydro, ipp, Malema, Mouvex, Neptune, Quantex, Quattroflow, and Wilden. PSG products are manufactured on three continents – North America, Europe and Asia – in state-of-the-art facilities that practice lean manufacturing and are ISO-certified. PSG is part of the Pumps & Process Solutions segment of Dover Corporation. For additional information on PSG, please visit psgdover.com. PSG: Where Innovation Flows.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 70 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." Additional information is available at dovercorporation.com.   

CPC Biotech Contact:
Jana Stender 
(612) 564-2053
jana.stender@cpc-bio.com

Dover Media Contact:
Adrian Sakowicz, VP, Communications
(630) 743-5039
asakowicz@dovercorp.com 

Dover Investor Contact:
Jack Dickens, VP, Investor Relations
(630) 743-2566
jdickens@dovercorp.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cpc-biotech-collaborates-with-multiply-labs-to-advance-cell-therapy-automation-302783353.html

SOURCE Dover

FAQ

What did CPC Biotech announce on May 27, 2026, related to Dover (NYSE:DOV) and cell therapy automation?

CPC Biotech announced a collaboration with Multiply Labs to advance robotic systems in cell therapy manufacturing. According to CPC Biotech, the partnership focuses on a robot-optimized aseptic connector using MicroCNX Nano Series technology to support faster, more efficient and high-quality cell therapy production.

How could the CPC Biotech and Multiply Labs collaboration affect cell therapy manufacturing for Dover (NYSE:DOV)?

The collaboration aims to enable robotics-based cell therapy manufacturing by providing connectors that robots can handle reliably. According to CPC Biotech, this may help reduce manual bottlenecks, lower contamination risk and support scalable, high-quality manufacturing that could improve access to advanced cell and gene therapies.

What is CPC Biotech's new robot-optimized aseptic connector mentioned in the DOV news?

CPC Biotech is developing a first-of-its-kind aseptic connector specifically designed for robotic operation in cell therapy manufacturing. According to CPC Biotech, it combines MicroCNX Nano Series connectors with a rigid proprietary interface engineered for robotic grippers, improving stable, repeatable handling of tubing in automated processes.

How does Multiply Labs' modular robotic system support cell therapy production for partners like Dover (NYSE:DOV)?

Multiply Labs uses a modular robotic system for cell and gene therapy production that avoids human entry into sterile environments. According to Multiply Labs, this design aims to reduce contamination risk, address manufacturing bottlenecks and broaden access by improving the scale and affordability of advanced therapies.

Why do CPC Biotech and Multiply Labs emphasize robotics for scaling cell therapy manufacturing tied to DOV?

They view robotics as essential to scaling cell therapy beyond traditional manual methods. According to CPC Biotech and Multiply Labs, robotic automation can support reliability, repeatability, simplification and compact footprints, helping manufacturers increase production capacity while maintaining sterile conditions and improving patient access to advanced therapies.

What role does the MicroCNX Nano Series technology play in CPC Biotech's collaboration related to Dover (NYSE:DOV)?

MicroCNX Nano Series connectors are the core aseptic connection technology in CPC Biotech's new robot-optimized solution. According to CPC Biotech, pairing these connectors with a proprietary rigid interface enables robotic grippers to manipulate tubing connections consistently inside self-contained sterile processing systems.